Ariceum Therapeutics Announces New CEO to Lead the Company
David Schilansky has taken the helm as the Chief Executive Officer of Ariceum Therapeutics, a trailblazer in the field of targeted radiotherapeutics. With a robust experience of 25 years in company-building and financing, Schilansky is poised to guide the company into a new era of growth and development.
Transitioning Leadership at Ariceum
The leadership transition comes as a strategic move to harness Schilansky's expertise, who previously served as the Chief Financial Officer. He succeeds Company Co-Founder and former CEO Manfred Rüdiger, PhD, who remains involved as a strategic advisor.
David Schilansky's Vision and Strategy
Upon his appointment, Schilansky expressed his enthusiasm for leading Ariceum through its next chapter. He acknowledged the pivotal role of Rüdiger in shaping the company’s successes and highlighted Ariceum's commitment to redefining cancer treatment paradigms, particularly with its lead candidate, 225Ac-SSO110. This innovative therapy targets extensive-stage small cell lung cancer (ES-SCLC) and Merkle cell carcinoma (MCC), which are associated with limited treatment options.
Exciting Clinical Developments Ahead
The company is gearing up for the Phase 1/2 SANTANA-225 study involving 225Ac-SSO110, with preliminary data expected to be available in the future, marking a significant advancement in its clinical pipeline. This research could potentially yield groundbreaking insights into the efficacy of radiotherapeutics in treating difficult cancers.
Strengthening the Executive Team
To further support its objectives, Ariceum has announced notable changes within its executive team. Germo Gericke continues as Chief Medical Officer, while Susanna Mesa steps into the role of Chief Operating Officer, bringing extensive experience in global operations and strategy for biotech companies. Manuel Sturzbecher-Höhne, PhD, has been promoted to Chief Technology Officer.
Commitment to Innovation and Patient Care
The team at Ariceum is driven by a desire to enhance patient outcomes through innovative science. Schilansky emphasized the company's focus on advancing radioligand therapy (RLT) and improving treatment efficacy for patients facing aggressive cancers.
Industry Support and Collaboration
Ariceum Therapeutics has garnered backing from prominent investors in the life sciences sector, ensuring that the company has the financial resources to propel its projects forward. This support is crucial as it continues to expand its reach across markets in Germany, Switzerland, Australia, the United Kingdom, and the United States.
Looking to the Future
Under Schilansky's leadership, Ariceum Therapeutics is set to redefine the landscape of cancer treatment. His strategic vision combined with a dedicated team aims not only to advance their novel therapies but also to set new standards in care for patients worldwide.
Frequently Asked Questions
What is the main focus of Ariceum Therapeutics?
Ariceum is focused on developing targeted radiotherapeutics for aggressive and hard-to-treat cancers, with an emphasis on innovative treatment options.
Who has been appointed as the new CEO of Ariceum?
David Schilansky has been appointed as the new Chief Executive Officer of Ariceum Therapeutics.
What is the lead candidate for Ariceum's clinical studies?
The lead candidate is 225Ac-SSO110, targeting extensive stage small cell lung cancer (ES-SCLC) and Merkel cell carcinoma (MCC).
What are the expected timelines for Ariceum's clinical trials?
The Phase 1/2 SANTANA-225 study is underway, with initial safety data anticipated in early 2026.
How is Ariceum supported in its initiatives?
Ariceum Therapeutics is backed by leading global life sciences investors, ensuring financial stability and support for its innovative projects.
